Autism spectrum disorder (ASD) is defined by the triad of deficits in social interactions, deficits in communication, and repetitive behaviors. Common co-morbidities in syndromic forms of ASD include intellectual disability, seizures, and obesity. We asked whether very obese children with ASD had different behavioral, physical and genetic characteristics compared to children with ASD who were not obese. We found that very obese children with ASD had significantly poorer scores on standardized behavioral tests. Very obese boys with ASD had lower full scale IQ and increased impairments with respect to stereotypies, communication and social skills. Very obese girls with ASD had increased impairments with respect to irritability and oppositional defiant behavior. We identified genetic lesions in a subset of the children with ASD and obesity and attempted to identify enriched biological pathways. Our study demonstrates the value of identifying co-morbidities in children with ASD as we move forward towards understanding the biological processes that contribute to this complex disorder and prepare to design customized treatments that target the diverse genetic lesions present in individuals with ASD.
Introduction
Autism spectrum disorder (ASD) has complex origins with contributions from genetic and environmental factors. As more genes are identified in which sequence variants contribute to ASD predisposition, it can be useful to determine whether mutations in certain genes are responsible not only for ASD, but also for co-morbid conditions that define syndromic forms of ASD (Miles 2011) . Fragile X syndrome, Angelman syndrome, Rett syndrome and a syndrome associated with POGZ mutations (Stessman et al. 2016) are examples of syndromes with defined genetics that have high rates of behavioral phenotypes either fitting the definition of ASD or closely mimicking ASD (Casanova et al. 2016 ). Other syndromes with defined genetics and with elevated risks of ASD include Down syndrome (Channell et al. 2015) , del16p11 syndrome , Bardet-Biedl syndrome (Kerr et al. 2015) , and Prader-Willi syndrome (PWS) (Dimitropoulos et al. 2013) . However, in the latter syndromes, how the loss of specific genes confers increased risk of ASD is still unclear. For example, the expression of multiple contiguous genes is disrupted in PWS. However, mutations in only one of the inactivated genes, namely MAGEL2, cause a PWS-like syndrome called Schaaf-Yang syndrome (Schaaf et al. 2013; Soden et al. 2014; Fountain et al. 2017) . Inactivating mutations in MAGEL2 also carry a very high risk of ASD, suggesting that loss of MAGEL2 also contributes to the increased incidence of ASD in children with PWS.
Children with ASD have an increased risk of overweight and obesity (Broder-Fingert et al. 2014; Dreyer Gillette et al. 2015; Hill et al. 2015; Jones et al. 2016) . However, the genetic contribution to the co-morbidity of obesity in ASD has not been systematically studied (D'Angelo et al. 2013; Ramachandrappa et al. 2013 ). While rising rates of obesity in adults have been attributed to societal changes in physical activity and food choices, severe childhood obesity more often involves changes in the central neural circuits that regulate food intake and energy expenditure (Farooqi 2014) . In principle, ASD and obesity could cooccur in an individual because of a single inherited or sporadic genetic mutation [e.g. deficiency of MAGEL2 or the transcriptional repressor MYT1L (Blanchet et al. 2017 )], two inherited or sporadic genetic mutations (one gene responsible for ASD and a different gene responsible for obesity), or a combination of genetic mutations and multifactorial contributions. Indeed, a variety of circumstances such as reduced activity, medication-induced weight gain, access to health care, and interrupted sleep patterns may contribute to obesity in ASD probands (Broder-Fingert et al. 2014; Hill et al. 2015) . Some probands could have an inherited predisposition to obesity that is unrelated to their ASD diagnosis, such as variation in the melanocortin-4 receptor, leptin, leptin receptor or FTO genes (Choquet and Meyre 2011) .
ASD-and obesity-predetermining genes participate in a large variety of biological processes, many of which affect the function of central neural circuits. Proteins important for ion transport and chromatin remodeling are common sources of mutations in autism gene sets (Schmunk and Gargus 2013) . The planar cell polarity (PCP) and Wnt-beta catenin pathways that control cell polarity and adhesion have been implicated in both autism (De Ferrari and Moon 2006; Hormozdiari et al. 2015; Caracci et al. 2016) and in the hypothalamic regulation of energy balance (Helfer and Tups 2016) . A key player is the ASD-associated gene CTNNB1, encoding beta catenin, in which mutations cause intellectual disability (ID)/ASD with neonatal hypotonia and respiratory problems Ye et al. 2014) . Mutations in a set of genes important for PCP pathways and ciliary function cause Bardet-Biedl syndrome, a neurodevelopmental disorder associated with intellectual disability and obesity (Ross et al. 2005 ).
An excess of de novo copy number variants (dnCNVs) in probands (0.05 per individual) compared to siblings (0.02 per individual) and a larger number of genes contained within proband dnCNVs compared to sibling dnCNVs are found in autism cohorts, suggesting that dnCNVs are associated with risk of ASD (Sanders et al. 2012) . Whole exome sequencing studies have estimated an average of 0.17 de novo likely gene disrupting (dnLGD) and 0.94 de novo nonsynonymous coding mutations (dnNSC) per affected child, also in excess over the de novo events in the control siblings (Iossifov et al. 2012; Sanders et al. 2012) . Most recent estimates have implicated at least 8 CNVs and 65 genes with increased risk for ASD (Krishnan et al. 2016) . We hypothesized that candidate genes for ASD with severe obesity could be identified by analyzing genetic variants found in very obese children with ASD from the Simons Simplex Collection (SSC) (Fischbach and Lord 2010) .
Methods

Probands and siblings
At the time of study, the SSC Version 15 Phenotype Data Set 9 contained data on 2873 probands with ASD, their parents, and one or more siblings (SFfA 2017). The data include psychological and IQ testing, medical history, dysmorphology, birth order, and anthropometric information. Details of phenotypic data are available from SFARI Base (sfari. org/resources/autism-cohorts/simons-simplex-collection). Height Z score, body mass index (BMI), and BMI-Z score were drawn from the SSC dataset for each proband and designated unaffected sibling. As with height, normal ranges of BMI vary with age in children, so the use of Z scores rather than absolute values allowed standardized comparison of children from 3 to 18 years of age. Height-Z and BMI-Z scores were pre-calculated in the SSC dataset using the World Health Organization growth standards and the age at evaluation from the SSC "height, weight, and head circumference" form.
Genes
Genetic mutations in SSC probands were derived from data in GPF: genotype and phenotype in families (Lab I GPF 2017) . Constraint scores defining tolerance to genetic mutation were derived from Exome Aggregation Consortium (ExAC) data (Lek et al. 2015) . Intolerance to mutation is assumed when the observed number of mutations (missense or loss of function) is significantly less than the number of mutations expected.
Statistics
Comparisons between groups of probands were performed by Student t test followed by post-hoc comparisons with Bonferroni corrections and a value of P < 0.05 for significance. Data in Table 1 were analyzed by Student t test. Data in Table 2 were analyzed by the PANTHER Overrepresentation Test (release 20170413) using a Bonferroni post hoc correction for multiple testing (Mi et al. 2017) . Data in Table 3 and Suppl. 
Results
Relationships between body mass index and anthropometric measurements, IQ, and neonatal history in SSC probands
We assessed the relationships between BMI and other anthropometric measurements, IQ, behavior, and neonatal history in the SSC SFARI Base, which contains data on probands with ASD, their parents, and siblings when available (SFfA 2017). Age, height-Z, and BMI-Z scores were available for 2246 male probands and 338 female probands (Fig. 1) . The mean BMI-Z of probands (0.66 ± 1.38, mean ± SD) was slightly larger than that of unaffected siblings (0.55 ± 1.27, Student t test, P = 0.01). More probands than siblings had a BMI-Z ≥ 2 (18 vs. 13%, Fisher's exact test, P < 0.0001). These data are consistent with previous reports of increased risk of obesity in children with ASD (Broder-Fingert et al. 2014; Dreyer Gillette et al. 2015; Hill et al. 2015; Jones et al. 2016) . Mean height-Z of probands (0.4 ± 1.1 for males and 0.2 ± 1.2 for females) was similar to that of unaffected siblings (Student t test).
Mother's BMIs (mean 27 ± 7 kg/m 2 ) and father's BMIs (mean 29 ± 6 kg/m 2 ) were calculated from their weight and height when available. Both weight and height have large genetic and environmental components, so we expected that probands with higher BMI would have parent(s) with higher BMI. Consistent with this prediction, 7% of obese probands with BMI-Z ≥ 2 had one or two severely obese parents (BMI ≥ 35), whereas 2.5% of probands with − 2 ≤ BMI-Z ≤ 2 had one or two severely obese parents. This suggests that some probands with high BMI for age have an inherited predisposition to obesity, while others, particularly those with normal weight parents and siblings, may also carry deleterious mutations in obesity-predisposing genes. We next tested whether there is a relationship between BMI-Z, ASD symptoms and full scale IQ (FSIQ) among SSC probands. In females, BMI-Z and FSIQ were not correlated. However, compared to typical weight males (− 2 ≤ BMI-Z ≤ 2), mean FSIQ was 12 points lower among very obese males (BMI-Z ≥ 3) ( Table 1) . Obese male probands (BMI-Z ≥ 2) and underweight male probands (BMI-Z ≤ − 2) also had significantly lower FSIQ than typical weight males. Verbal IQ was 13 points lower in very obese males compared to typical weight males. Consistent with a previous study (Kerekes et al. 2015) , mean scores for some behaviors were worse in very obese compared to typical weight children with ASD: very obese males had increased impairments with respect to stereotypies on the Aberrant Behavior Checklist (ABC), overall language on the Autism Diagnostic Interview (ADI), social problems, somatic problems and complaints, and total competence on the Child Behavior Checklist (CBCL 6-18), awareness and communication on the teacher version of the Social Responsiveness Scale, and in communication, daily living skills, and socialization on the Vineland Adaptive Behavior Rating Scales (VABS) (Fig. 2) . Very obese females with ASD had larger impairments with respect to irritability (ABC) and aggressive and oppositional defiant behaviors (CBCL) compared to typical weight females (Fig. 2) . It is important to note that many of these measures are correlated with each other: for example, lower IQ is correlated with increased stereotypies (Goldman et al. 2009 ). There were no behaviors that were less impaired in the very obese group in any of the scales used.
In humans, increased paternal age correlates with an increased number of de novo mutations in offspring at about two mutations per year (Kong et al. 2012 ). However, Sanders et al. found no evidence for a correlation between the number of de novo mutations per proband and parental age in the SSC. We examined paternal age in very obese SSC probands, using birth order as a surrogate index for parental age. Very obese male probands had a higher average birth order (2.0 ± 0.9) compared to typical weight male probands (1.7 ± 0.8, P < 0.0001), and so are expected to have slightly older parents. However (see below), there was no evidence that very obese probands had more de novo mutations than probands of typical weight.
We next examined SSC phenotypic data to determine whether obese or very obese SSC probands had other clinical findings that could suggest a syndromic form of autism. We were particularly interested in neonatal history, given that neonatal hypotonia or difficulty feeding are found in many neurodevelopmental disorders. Of 2591 SSC probands, 19% reported some neonatal complication (Fig. 3) . The most common neonatal complications were difficulty feeding and respiratory problems (in 19%), poor suck (10%), or decreased muscle tone (7%). APGAR scores at 1 min were reported to be below 7 in 5% of infants, and 7% were admitted to the NICU. These data represent minimum prevalence, as the absence of a report does not necessarily mean that the phenotype was not present. The prevalence of most neonatal complications was similar for probands who later presented as underweight (BMI-Z ≤ − 2, n = 66), obese (BMI-Z ≥ 2, n = 465), or very obese (BMI-Z ≥ 3, n = 119). There was a trend towards a higher incidence of "stiff infant" among the underweight class and a trend towards higher incidence of broken bones reported in the very obese class, but these trends were not statistically significant after accounting for multiple comparisons (Fig. 3) . 
Genetic analysis of very obese probands in the SSC
We used GPF: genotype and phenotype in families to identify de novo mutations in 133 probands with BMI-Z ≥ 3 (10 F, 123 M) (Lab) . We limited the search to variant types sub, ins, del, or CNV with effect types coding (Nonsense, Frame-shift, Splice-site, Missense, Nonframe-shift, noStart, noEnd) or CNV (+ or −). There were 120 such de novo mutations, including 17 dnCNVs, 20 dnLGD, frame-shift, nonsense, or splice-site mutations and 83 mutations of the remaining varieties (Suppl. Table 1 ). The number of de novo mutations per very obese proband was not different from the number of de novo mutations per typical weight proband. Some probands had de novo mutations in more than one category. Three dnCNVs in very obese probands had already been associated with ASD risk (Mervis et al. 2015; Sanders et al. 2015; DiStefano et al. 2016; Hippolyte et al. 2016) (dup7q11, dup15q12, del16p11) . Both the dup15q12 and del16p11 CNVs are also associated with obesity (Walters et al. 2010 ).
Analysis of de novo loss of function and missense mutations
Of the 20 genes with dnLGD mutations in very obese probands, 11 had already been associated with ASD in SFARI Gene (Research) (ANK2, DNMT3A, DSCAML1, MYH10, POGZ, PPM1D, PSD3, PTK7), OMIM (VCP) or in neurodevelopmental disorders (Stessman et al. 2016; Guo et al. 2017) (SPEN, STAM) . Only two of these genes have been associated with overgrowth: DNMT3A and POGZ. The proband identified here is the only one in the SSC with a dnLGD mutation in DNMT3A (DNA-methyltransferase 3 alpha). DNMT3A is mutated in children with Tatton-Brown-Rahman syndrome, which is associated with tall stature, a distinctive facial appearance, and intellectual disability. with BMI-Z = 2, both consistent with White-Sutton syndrome. Inactivating mutations in PTK7 (encoding a tyrosine-protein kinase), and inherited or de novo mutations in PPM1D (encoding a protein phosphatase) have been found in children with ASD (Sanders et al. 2012; De Rubeis et al. 2014) . The female with a PPM1D mutation also carries a dnNSC in SCN1A, encoding a sodium channel associated with epilepsy, and a dnLGD mutation in TNFRSF8. dnLGD mutations in MYH10 (encoding a non-muscle myosin) have been found in children with moderate to severe ID (De Rubeis et al. 2014; Dong et al. 2014; Hamdan et al. 2014; Iglesias et al. 2014) . Heterozygous LGD mutations in VCP (valosin containing protein) cause amyotrophic lateral sclerosis with dementia or myopathy (Weihl et al. 2009 ). The male with a VCP dnLGD mutation also carried a dnNSC in SCN4A, a gene mutated in autosomal dominant and autosomal recessive muscular conditions. The other ten genes in which dnLGD mutations were found have not been associated with neurodevelopmental genetic disorders to date. 
Consideration of tolerance to mutation for ASD/ obesity candidate genes
We next considered the tolerance of the candidate genes to either loss of function (LoF) or missense mutations using the ExAC interface (Lek et al. 2015) . Reduced tolerance would be expected of a gene for which haploinsufficiency reduces fertility, and would increase the likelihood that the de novo mutation is pathogenic. Of the genes with dnLGD mutations, ten previously identified ASD/ID genes were intolerant to LoF, missense or both (ANK2, DNMT3A, DSCAML1, 
MYH10, POGZ, PPM1D, PTK7, SPEN, STAM, and VCP).
Of the remaining dnLGD genes, some were highly intolerant to LoF mutations (CDC23, SPAG9) or to missense mutations (CDC23) while the remaining were tolerant to both LoF and missense mutations. Of the genes in which there were dnNSC mutations in very obese probands, some were intolerant to either missense or LoF mutations, including genes associated with neurodevelopmental disorders (GLRA2, GRM7, KMT2C, MEGF8, PTK7, RYR1, SCN1A, TRIP12) . Other genes not yet associated with disorders were also deemed intolerant to either missense or LoF mutations, while the remaining genes were either tolerant or of unknown tolerance (Suppl. Table 1 ).
Gene Ontology pathways identifies proteins important for neuronal action potentials as contributors to ASD in very obese probands
We used Gene Ontology (GO) and ClueGO (Bindea et al. 2009 ) to identify pathways enriched in the de novo mutated gene set compared to expected for all GO-annotated genes in the genome (Ashburner et al. 2000) . This analysis is constrained by the fact that the very obese group differs from the typical weight group not only in high BMI-Z but also in lower IQ (Table 1 ) and more severe behavioral scores (Fig. 2) , so that the genes mutated in this group may contribute to ASD or any one of these co-morbid phenotypes. The combined set of mutated genes (dnLGD and dnNSC) is significantly enriched in genes involved in neuronal membrane depolarization during action potential and voltage-gated ion channel activity (ANK2, ANK3, ANO9, ELK1, GLRA2, GRM7, NLGN2, RYR1, SCN1A, SCN3A, SCN4A, SCN11A, SLC17A3, TRPM6, VCP) ( Table 2 ). Analysis of missense mutations alone produced a similar profile of disruption of neuronal action potential (data not shown). ClueGO uses both GO terms and KEGG (Kyoto Encyclopedia of Genes and Genomes-GenomeNet)/BioCarta pathways to create a functionally organized network based on both GO and pathway terms. ClueGO analysis of the combined set of de novo mutated genes confirmed the biological enrichment for neuronal action potential and membrane depolarization and the molecular enrichment for ion channel activity (Suppl. Table 2 ). ClueGO also detected an additional cellular enrichment for GOTerms "intercalated disc", "T-tubule", and "I band", which all relate to cytoskeletal components and cell cell junctions related to muscle fibers (Suppl. Table 2 ). We next used ClueGO to perform a REAC-TOME pathway enrichment analysis, which does not depend on GO terms (Table 3 ). This confirmed the enrichment predicted by GO analysis for stimuli sensing channels, depolarization, and voltage-gated sodium and potassium channels. Interestingly, this analysis revealed an enrichment for ankyrins, cell adhesion molecules, and interactions between ankyrins and cell adhesion molecules. These interactions play a key role in axon growth during central nervous system development (Gil et al. 2003) . Re-analysis using only genes that are intolerant to mutation confirmed the REACTOME pathway enrichment of "interaction between cell adhesion molecules and ankyrins".
Planar cell polarity/Wnt signaling genes are also mutated in obese probands
We next used a candidate gene approach to investigate whether genes previously implicated in obesity pathways were identified among the mutated gene in obese SSC probands. Intriguingly, all three SSC probands who carry de novo mutations in the PCP/Wnt pathway PTK7 gene (Martinez et al. 2015) are very obese (Suppl. Table 3 ). PCP pathways intersect with phosphoinositide three-kinase (PI3K) pathways, and three additional very obese probands carry de novo mutations in the PI3K pathway genes PSD3, MYH10, and ANK3 respectively. We further investigated PCP/Wnt pathway genes in obese probands in the SSC (i.e. BMI-Z ≥ 2), because of the relationship between this pathway and syndromic forms of obesity like Bardet-Biedl syndrome (Ross et al. 2005 ). An obese SSC proband (BMI-Z = 2.5) carries a dnLGD mutation in DVL3, one of the three human genes encoding forms of the Wnt relay protein Dishevelled (Bunn et al. 2015 ). This proband had neonatal feeding difficulties and physical anomalies including genital anomalies. Another obese SSC proband (BMI-Z = 2.5) carries a dnLGD mutation in NOTCH1, encoding a Dishevelled antagonist. This proband had neonatal feeding difficulties, and was stiff at birth, phenotypes also seen in infants with Adams-Oliver syndrome caused by NOTCH1 mutations (Stittrich et al. 2014) . CNTN6 encodes a NOTCH signaling pathway protein (contactin) and is mutated in a very obese proband (Kashevarova et al. 2014 ). Yet another obese SSC proband (BMI-Z = 2.7) carries a dnLGD mutation in MED13L, a gene associated with ID with transposition of the great arteries, and implicated in Wnt signaling (Utami et al. 2014 ). This proband had neonatal respiratory distress, feeding difficulty, and other unspecified defects. The protein encoded by SPEN (dnLGD) has an emerging role in ciliary function, fat cell regulation, and neurite outgrowth (Gu et al. 2017; Hazegh et al. 2017; Legare et al. 2017) . Last, we looked at the DYRK1A gene, encoding a kinase that inactivates GSK3-beta and is implicated in neurodevelopmental disorders with co-morbid autism (Song et al. 2015) . Of four probands in the SSC with DYRK1A mutations, three were obese and two had multiple neonatal complications. The Wnt/PCP genes PTK7, RAPGEF2, CTNNB1, DVL3, MED13L, DYRK1A, and NOTCH1 are all highly intolerant to LoF mutations, supporting their essential role in development. There were no loss of function mutations in the SSC collection in genes responsible for Bardet-Biedl syndrome, which is also a disorder of planar cell polarity. This is likely because children with Bardet-Biedl syndrome typically develop blindness and deafness, which would exclude them from the SSC.
We next considered a potential role for the MUC genes in ASD with high BMI. The encoded mucin proteins are aberrantly regulated through Wnt-dependent pathways in tumors, particularly in cancers of the gastrointestinal tract. Variants in MUC5B are associated with type 2 diabetes . Recurrent de novo nonsynonymous mutations in the MUC5B gene have previously been noted in cohorts of patients with autism or intellectual disability. However, MUC5B has been previously excluded as an ASD candidate gene because of high variation in controls (Hoischen et al. 2014) . In contrast, ExAC analysis suggests that MUC5B is highly constrained for both missense and LoF mutations despite a high absolute number of variants in controls. All five probands in the SSC collection carrying MUC5B mutations had neonatal complications, and two were obese with BMI-Z = 3.0 (missense mutation) and BMI-Z = 2.9 (nonsense mutation) (Suppl. Table 4) .
Last, genes encoding proteins important for endosomal sorting, protein ubiquitination and autophagy, pathways recently implicated in neurodevelopmental and neurodegenerative disorders (Tang et al. 2014) were also analyzed further. This analysis was motivated by the finding that mutations in the MAGEL2 gene cause ASD in Schaaf-Yang syndrome and contribute to obesity and ASD in Prader-Willi syndrome through disruption of endosomal protein trafficking (Hao et al. 2013; Schaaf et al. 2013; Soden et al. 2014; Fountain et al. 2017) . Genes associated with these pathways and mutated in very obese probands include VCP (valosin containing protein, mutations associated with ubiquitinated inclusions and protein aggregates in cells, frontotemporal dementia with myopathy, vesicle transport and fusion), STAM (component of the endosomal sorting complex), and SPAG9/JIP4 (kinesin-mediated transport in neurons).
Discussion
The Simons Simplex collection is a well-characterized cohort of individuals with autism spectrum disorder, for whom a rich variety of clinical data has also been collected. By its nature, individuals with ASD but also a diagnosis of a syndromic genetic disorder, such as Prader-Willi syndrome or Bardet-Biedl syndrome, are underrepresented in or excluded from SSC. As observed in other autism cohorts, probands in the SSC are overweight compared to unaffected siblings. We postulated that probands in the SSC at extreme ends of the phenotypic ranges for various traits could inform us about as yet unrecognized subtypes of ASD. Indeed, we found that very obese male SSC probands had lower full scale and verbal IQ compared to typical weight probands, and also had significantly worse scores in the areas of communication, daily living skills, and socialization. More severe behaviors were also seen in very obese female probands, but the smaller number of girls compared to boys represented in the SSC limited this analysis. We cannot exclude the possibility that being very obese in and of itself impairs social communication because of exclusion from activities with peers. Conversely, more severe behaviors could contribute to obesity because the child may be excluded from activities that promote fitness. Our study is also compromised by the considerable environmental contribution to the obesity phenotype, particularly in a country that has seen childhood obesity rates increase substantially in the last few decades. Limiting the analysis to very obese probands with two lean parents might have mitigated some of this confounding variable, but would have also reduced the sample size to an unmanageably small number of probands. As well, we cannot distinguish between excessive food intake (hyperphagia) and reduced activity as the cause of obesity in probands. We did not find that neonatal complications were associated with obesity in this study, although the lack of reporting of neonatal histories limited this analysis.
We proposed that genetic investigation of individuals with dual diagnoses of ASD and obesity could point us towards pathways that are essential for normal neurodevelopment and normal development of energy-regulating pathways. Obese probands do not appear to have more pathogenic mutations compared to typical weight probands with ASD. Despite analyzing over 2000 probands, we could not determine whether some probands had mutations in two different genes or environmental factors that independently contributed to ASD and obesity. We also only examined de novo mutations, and so do not have information about other genetic mechanisms, such as recessive mutations that may contribute to either the obesity or ASD phenotypes.
Our focus on de novo mutations in very obese probands correctly identified obesity predisposing lesions such as del16p11 and loss of function mutations in DNMT3A and POGZ and support a role for mutations in PTK7 in autism (Sanders et al. 2015) and also in obesity. Additional very obese probands carried mutations in genes implicated in ASD or other neurological disorders, such as those important for neuronal action potentials, as predicted from previous autism analyses (Glessner et al. 2009; Chahrour et al. 2012) and genes involved in axon growth through interactions between ankyrins, which are adaptor proteins that mediate binding between membrane proteins and the membrane cytoskeleton, and cell adhesion molecules (ANK2, ANK3, DSCAML1, SCN1A, SCN3A).
The PCP/Wnt pathway has been implicated in neurodevelopmental disorders associated with neonatal 1 3 complications and obesity, in part through the identification of key genes such as CTNNB1, MIB1, RAB23, MEGF8, PTK7, and the BBS genes in syndromic forms of intellectual disability. PTK7 encodes protein tyrosine kinase 7 and is implicated in Wnt signaling pathway. PTK7 (CCK4) binds intracellular scaffolding proteins of the Dishevelled family that act downstream of WNT receptors. PTK7 has mostly been studied in the context of cancer cell motility and in epithelial to mesenchymal transitions during development. A recessive Ptk7 mutation in mice (chuzhoi) causes severe developmental defects consistent with dysregulation of PCP, but no phenotype has been described in chuzhoi heterozygotes. Loss of ptk7 function in zebrafish causes ciliary and PCP abnormalities. In humans, we would not expect to find homozygous mutations, considering that this state is embryonic lethal in mice. It would however be interesting to determine whether chuzhoi heterozygous mice have behavioral abnormalities recapitulating ASD. The endosomal sorting/ubiquitination pathways have also been implicated in syndromic intellectual disability, with mutations in MAGEL2, VPS13B, and VCP causing syndromic neurological disorders. Our data support the previously noted involvement of both the PCP/ Wnt pathway and the endosomal sorting/ubiquitination pathway in ASD. There are too few probands with obesity and ASD and de novo mutations to determine whether this pathway is indeed enriched in the very obese subgroup of children with ASD. Further investigation of these two pathways in ASD may be warranted. In particular, genes that are mutated in obese probands with ASD and in many cases also intolerant to mutation (BTBD9, DVL3, MED13L, RAPGEF2, RYK, STAM, and SPAG9) may be good candidates for involvement in syndromic forms of ASD. Interestingly, we did not detect an enrichment for genes important for hypothalamic development or function, despite evidence that haploinsufficiency for some of these genes causes syndromic obesity with intellectual disability/ASD [e.g. MYT1L (Blanchet et al. 2017) and SIM1 (Walters et al. 2010; Ramachandrappa et al. 2013) ].
In conclusion, our study provides a model for gene discovery using additional phenotypic information to categorize subsets of ASD probands. For example, probands with dysmorphic features could have a different set of genetic lesions compared to those without dysmorphic features. Extensive phenotypic characterization and collection of a larger cohort of children with ASD, as is now ongoing in the Simons Foundation Powering Autism Research for Knowledge initiative (SPARK) will enrich our understanding of the multitude of genes associated with the many flavors of autism spectrum disorder. This understanding is essential for the design of customized therapies that target the underlying genetic lesion that contributes to the diagnosis of ASD in each individual.
